No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACXP240621C2000
- 0.35
- -0.09-20.45%
15min DelayClose Jun 20 15:49 ET
0.35High0.35Low
0.35Open0.44Pre Close1 Volume15 Open Interest2.00Strike Price35.00Turnover462.12%IV5.38%PremiumJun 21, 2024Expiry Date0.23Intrinsic Value100Multiplier1DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.7100Delta0.5986Gamma6.37Leverage Ratio-0.1114Theta0.0000Rho4.52Eff Leverage0.0004Vega
Intraday
- 5D
- Daily
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersRezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago
Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Express News | HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Acurx Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 433.33% HC Wainwright & Co. $12 → $12 Reiterates Buy → Buy 03/19/2024 433.33% HC Wainwright & C
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid Financials
Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...
Comments
$Acurx Pharmaceuticals(ACXP.US$ Reuters· just
Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program
Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program
$Acurx Pharmaceuticals(ACXP.US$
NEWS
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.
NEWS
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.
$Acurx Pharmaceuticals(ACXP.US$ Acurx Pharmaceuticals Withdraws Filing for Stock Offering
Dow Jones· 7 mins ago
Dow Jones· 7 mins ago
$Acurx Pharmaceuticals(ACXP.US$ Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
8
$Acurx Pharmaceuticals(ACXP.US$ Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
2 MINUTES AGO, 7:00 AM EST
VIA PR NEWSWIRE![]()
2 MINUTES AGO, 7:00 AM EST
VIA PR NEWSWIRE
Read more